Lv3
235 积分 2021-04-03 加入
Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial
5小时前
求助中
Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial
5小时前
已完结
Dexamethasone in Patients with Spontaneous Intracerebral Hemorrhage: An Updated Meta-Analysis
4个月前
已完结
Teaching neuromarketing to fashion students: an application of Kirkpatrick’s model
6个月前
已完结
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
10个月前
已完结
Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial
10个月前
已完结
First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects
10个月前
已完结
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
10个月前
已完结
PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes
10个月前
已完结
In early T2D inadequately controlled with diet and exercise, once-daily orforglipron reduced HbA1c vs. placebo at 40 wk
11个月前
已完结
皖公网安备34019202002308
